TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT05956041

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing Pembrolizumab and Mogamulizumab for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Pembrolizumab (DRUG): 400mg Intravenously | Mogamulizumab (DRUG): 1mg/kg Intravenously

Drugs / treatments
Pembrolizumab, Mogamulizumab
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

NCT05956041

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is testing Pembrolizumab and Mogamulizumab for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Pembrolizumab (DRUG): 400mg Intravenously | Mogamulizumab (DRUG): 1mg/kg Intravenously

Drugs / treatments: Pembrolizumab, Mogamulizumab

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 23 patients

Primary endpoint: Complete Response Rate

Ages: 18 Years to —

Start date: 2023-12-06 | Est. completion: 2027-12

Locations

1 US sites · 1 total

Michigan

Contact

Cancer AnswerLine | CancerAnswerLine@med.umich.edu | 1-800-865-1125

Sponsor: University of Michigan Rogel Cancer Center (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05956041

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.